Aestimo Insights


With greater than 45 years cumulative experience, we are experienced veterans in the life science industry, with substantial knowledge in health technology development working in and with small to big health technology development companies, international partnering, fund raising and strategic implementation.


Leveraging our experience in health technology development including health technology assessments (HTA s)  on a Global, Regional and country level we have developed a novel valuation model based on existing models integrating pre-clinical, clinical, HTA and commercial potential allowing for optimised value making decisions throughout the whole life cycle of intervention development.


Our own experience, indicated below have shown that there is a considerable disconnect of value perceptions, risk understanding, expectations, knowledge and value generation between stakeholders at the different ends of the development pathway, that has serious consequences when companies attempt to out-license its product to a larger company or attempt to launch a product into the marketplace to commercialise it.​

              Latest Aestimo Insight

A cloud or a perfect storm? Assessing current status and future needs in healthtech and healthcare related IT.



On the 25thof May 2018 the European General Data Protection regulation (GDPR) became a legal necessity. This necessary regulation has global ramifications due to the nature of personal data storage and handling with high relevance in health care; only 5 non-EU countries (Argentina, Uruguay, New Zealand, Japan and Israel (CNIL 2019)) are compliant with the regulation related to personal data handling. In the context of Cloud and IT deployment in healthcare it is also questionable whether Cloud deployed health IT systems are operating correctly or providing benefit. Within the healthcare sector, the structures of which are now moving to or have already moved to Cloud based architecture, the increasing privacy and regulatory constraints highlights the fragility of these systems when related to the total healthcare ecosystem. Generic IT infrastructure and data management system deployments, while seeming trendy and exciting solutions, maybe generating more long-term problems than expected.


                                                           Our full insight paper can be found here


In light of the recent recurrent data-abuse events that demonstrate the ease with which personal data can be misused and the stressed budget environment in healthcare, the accelerated digitization of almost every component of patient management may not be ideal. Without fully integrated and interfaced systems, including the stream of emerging healthtech solutions aimed at patients and healthcare practitioners alike, matched with a suitable support system of how to manage the data and what to do when it goes wrong, incorrect implementation may exacerbate mission critical failings that could lead to the whole system buckling, and not achieving the goal of reducing costs and providing better and preventative care.

The underlying and defining problem, is something common to many other healthcare innovations and their development; fundamentally all the stakeholders are not aligned in the design and decision making throughout the whole ecosystem meaning that solutions are generated in a fragmented mode, which do not integrate or interface with each other, the existing infrastructure or customer needs and capacities. This makes justification of the total cost and economic benefit of their development and implementation questionable and as such the possible benefits of the constantly evolving modern IT infrastructure maybe lost. Fundamentally a ‘new shiny toy’ is not going to help. Here we discuss the underlying fault lines in the system and solutions to lay a better foundation for cutting edge IT usage in healthcare.


Innovation Ecosystem design and  Strategy

Maximising outputs from early stage collaborations: link


A common apothecary cabinet – redesigning personalised medicine: link


2090..or 2020 – the future of regenerative medicine: link


Innovation case study (Transvac) – designing an international early stage innovation ecosystem: link

Increasing value with HTA

The Road To Return Of Investment Goes

Via Reimbursement. Link


Attracting Investors: The Value Of HTA. Link

A novel valuation model for healthcare technologies development. Link


The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. Link


Patient-Reported Utilities In Advanced Or Metastatic Melanoma, Including Analysis Of Utilities By Time To Death. Link


Modelling The Cost-Effectiveness Of Ipilimumab For Previously treated, Metastatic Melanoma. Link


A UK Based Cost-Effectiveness Analysis Of Dasatinib (Sprycel) 100mg Daily Compared To Imatinib (Glivec) 600/800mg Daily As Therapy For Imatinib Failing Chronic Myeloid Leukemia (Cml).Link


Advanced Cutaneous Melanoma In The UK: A Systematic Review. Link


An Economic Evaluation Of Dasatinib For The Treatment Of Imatinib Resistant Patients With Advanced Phase Chronic Myelogenous Leukaemia. Link


Cost-Effectiveness Of Saxagliptin Compared To Sitagliptin For The Treatment Of Patients With Type 2 Diabetes Mellitus (T2dm). Link


Costs Of Medication Nonadherence In Patients With Diabetes Mellitus: A Systematic Review And Critical Analysis Of The Literature. Link

Mental Health

The Cost-Effectiveness Of Aripiprazole In Patients With Bipolar I Disorder In The UK. Link


The Cost Effectiveness Of Aripiprazole For The Treatment Of Adolescents With Schizophrenia. Link

Infectious disease

Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. Nuijten M, Lebmeier M, Wittenberg W. J Med Econ. 2009;12(4):291-300. Link


Cost effectiveness of palivizumab in children with congenital heart disease in Germany. Link


Cost-Effectiveness Of Palivizumab Against Respiratory Syncytial Viral Infection In High-Risk Children In Austria. Link


Cost Effectiveness Of Palivizumab For Respiratory Syncytial Virus Prophylaxis In High-Risk Children: A UK Analysis. Link


The Cost-Effectiveness Of Palivizumab In Austria. Link


Cost-Effectiveness Model Of Palivizumab In The UK. Link


Cost-Effectiveness Model of Palivizumab In The Netherlands. Link

Clinical translation of innovations

What did Maxwells Equations really have to do with Edison´s Inventions? Addressing the complexity of developing clinical interventions for skeletal muscle disease: Link


NICE Guidance: An Analysis Of Levels Of Restriction By Disease Area: Link


Methodological Issues In The Literature On Costs Of Non-Compliance In Chronic Diseases. Link


The Medinet-Project - A Feasibility Study On Medication Compliance Under Real Life Conditions. Link

Stakeholder liaison

UK Government Consultation To Allow NICE To Charge Companies For Making Reimbursement Submissions. Why Especially Small Companies Should Respond. 



Socioeconomic needs – putting health value before financial gain: link


Patient power – the importance of patients and patient associations in intervention design and validation: link

Renal disease

Assessing The Future Burden Of Renal Replacement Therapy In The United Kingdom. Link


Evaluating The Minimum Renal Allograft Survival Time Required For Transplantation To Remain Cost Saving In The UK. Link

Inflammatory disease

Modelling The Cost-Effectiveness Of First-Line Biologics For Rheumatoid Arthritis In England And Wales. Link


Modelling The Cost-Effectiveness Of First Line Biologics For Rheumatoid Arthritis In Ireland. Link


Indirect Treatment Comparison Of Abatacept With Methotrexate Versus Other Biologic Agents For Active Rheumatoid Arthritis Despite Methotrexate Therapy In The United Kingdom.Link



Biologic Therapies For Rheumatoid Arthritis – Eligibility Criteria In The UK. Link


Abatacept With Methotrexate Versus Other Biologic Agents In Treatment Of Patients With Active Rheumatoid Arthritis Despite Methotrexate: A Network Meta-Analysis. link


Mixed Treatment Comparison Of Biologic Agents In Patients With Rheumatoid Arthritis Who Have Responded Inadequately To Methotrexate Therapy In The United Kingdom. Link


Cost-Effectiveness Of Abatacept For The Treatment Of Rheumatoid Arthritis (RA) After The Failure Of A First TNF Inhibitor In The United Kingdom. Link


Modeling Of Rheumatoid Arthritis: A Methodological Approach:Link


Indirect Treatment Comparison To Compare Efficacy In Health Assessment Questionnaire (HAQ) Score For Biologic Agents With Methotrexate In Patients With Rheumatoid Arthritis And Active Disease Despite Methotrexate Therapy.



The Cost-Effectiveness Of Abatacept In Combination With Methotrexate For The Treatment Of Patient With Active Rheumatoid Arthritis After An Inadequate Response To Methotrexate In The United Kingdom. Link


Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Link


Economic Evaluation Of Biologic Therapies For Moderate To Severe Psoriasis: Etanercept Compared To Adalimumab And Infliximab. Link


A Cost Comparison Of Adalimumab And Etanercept For The Treatment Of Chronic Plaque Psoriasis In The United Kingdom. Link


The Cost-Effectiveness Of Sequential Use Of Anti-Tumor Necrosis Factor Agents In The Treatment Of Rheumatoid Arthritis. Link


Economic Evaluation Of Etanercept Compared To No Systemic Therapy In The Management Of Less Severe Chronic Plaque Psoriasis In The UK.  Link


The Economic Implications Of Achieving Treatment Response In Patients With Rheumatoid Arthritis. link

Suite 7, The Courtyard, Carmanhall Road, Dublin, D18 NW62

CRO Number 648128


© 2019 by Aestimo Ltd.. Proudly created with